Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
Authors:
- Ammar MajeedAMAmmar Majeed
- Hun-Gyu HwangHHHun-Gyu Hwang
- Stuart J. ConnollySCStuart J. Connolly
- John W. EikelboomJEJohn W. Eikelboom
- Michael D. EzekowitzMEMichael D. Ezekowitz
- Lars WallentinLWLars Wallentin
- Martina BrueckmannMBMartina Brueckmann
- Mandy FraessdorfMFMandy Fraessdorf
- Salim YusufSYSalim Yusuf
- Sam SchulmanSSSam Schulman
Open Access
- 19 November 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 128 (21) , 2325-2332
Abstract
Background—: The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin. Methods and Results—: Two independent investigators reviewed bleeding reports from 1034 individuals with 1121 major bleeds enrolled in 5 phase III trials comparing dabigatran with warfarin in 27 419 patients treated for 6 to 36 months. Patients with major bleeds on dabigatran (n=627 of 16 755) were older, had lower creatinine clearance, and more frequently used aspirin or non-steroid anti-inflammatory agents than those on warfarin (n=407 of 10 002). The 30-day mortality after the first major bleed tended to be lower in the dabigatran group (9.1%) than in the warfarin group (13.0%; pooled odds ratio, 0.68; 95% confidence interval, 0.46–1.01; P =0.057). After adjustment for sex, age, weight, renal function, and concomitant antithrombotic therapy, the pooled odds ratio for 30-day mortality with dabigatran versus warfarin was 0.66 (95% confidence interval, 0.44–1.00; P =0.051). Major bleeds in dabigatran patients were more frequently treated with blood transfusions (423/696, 61%) than bleeds in warfarin patients (175/425, 42%; P P P =0.01). Conclusions—: Patients who experienced major bleeding on dabigatran required more red cell transfusions but received less plasma, required a shorter stay in intensive care, and had a trend to lower mortality compared with those who had major bleeding on warfarin. Clinical Trial Registration—: URL: http://www.ClinicalTrials.gov . Unique identifiers: NCT00262600, NCT00291330, NCT00680186, NCT00329238 and NCT00558259.Keywords
This publication has 32 references indexed in Scilit:
- Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderlyBMJ Open, 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismNew England Journal of Medicine, 2013
- Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or DabigatranStroke, 2012
- Evidence-Based Management of Anticoagulant TherapyChest, 2012
- Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor DabigatranStroke, 2011
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationCirculation, 2011
- Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran EtexilateClinical Pharmacokinetics, 2010
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007
- Toward Rational Fresh Frozen Plasma TransfusionAmerican Journal of Clinical Pathology, 2006
- Hematoma Growth and Outcome in Treated Neurocritical Care Patients With Intracerebral Hemorrhage Related to Oral Anticoagulant TherapyStroke, 2006